FDA Proposes Ban on Compounding Weight-Loss Drugs

0:00On April 30th, the FDA just dropped a proposal to slam the breaks on compounding popular weight-loss drugs. They're looking to yank the active ingredients from noble Nordisk and Eli Lilly's blockbuster meds off the list that outsourcing facilities can use. That means no more mixing semaglutide from wagovian ozempic, or tears apotide from zepbound and mojaro, plus novos older lira glutide. If this gets finalized, compounding these would only fly if the drugs hit the official shortage list. Right now, the FDA says there's no real clinical need for facilities to whip them up from bulk substances when the approved versions are out there. outsourcing spots have been cranking out cheaper knockoffs amid the obesity drug boom, but this move aims to protect patients from untested versions. Folks chasing quick weight loss have turned to these compounded options for lower prices and easier access. The FDA commissioner laid it out clear. When approved drugs are available, bulk compounding isn't legal without a proven medical gap.

1:01This proposal builds on rules to keep things safe and standardized. Expect public comments and tweaks before anything sticks, shifting the game back to our brand name supplies and potentially hiking costs for every day. Users, stay tuned as this shakes out. Stay informed with US News Today, AI-powered updates.